| dc.contributor.author | Plakida, A. | |
| dc.contributor.author | Moskal, O. | |
| dc.contributor.author | Gushcha, S. | |
| dc.date.accessioned | 2026-11-15T12:15:29Z | |
| dc.date.available | 2026-11-15T12:15:29Z | |
| dc.date.issued | 2026 | |
| dc.identifier.citation | Plakida A., Moskal O., Gushcha S. Obesity-associated gut dysbiosis: Metabolic dysfunction-associated steatotic liver disease as a clinical model of host–microbiome interactions // Microbes & Immunity. 2026. Vol.10, n.10. P. 1-17. doi: 10.36922/MI026270079 | uk_UA |
| dc.identifier.uri | https://repo.odmu.edu.ua:443/xmlui/handle/123456789/20583 | |
| dc.description.abstract | Obesity is associated with profound alterations in the composition and function of the gut microbiota that extend far beyond the gastrointestinal tract. Accumulating evidence indicates that obesity-associated gut dysbiosis influences intestinal barrier integrity, immune regulation, microbial metabolism, and systemic metabolic homeostasis through interconnected biological mechanisms. These alterations contribute to the development of chronic metabolic disorders affecting several organ systems. This review summarizes current knowledge regarding the host– microbiome interactions linking obesity-associated gut dysbiosis with metabolic dysfunction. Particular attention is given to the sequential interactions between microbial ecosystem remodeling, impaired intestinal barrier function, chronic low- grade inflammation, and metabolic disturbances that collectively promote obesity- associated diseases. Rather than focusing exclusively on liver pathology, metabolic dysfunction-associated steatotic liver disease is presented as one of the best- characterized clinical models demonstrating how disturbances originating within the gut microbiome evolve into systemic metabolic disease. Finally, emerging therapeutic strategies targeting the gut–microbiome axis are discussed, with emphasis on restoration of microbial homeostasis and early intervention aimed at interrupting pathophysiological progression before irreversible metabolic complications develop. These approaches may contribute to preventing or attenuating obesity-associated metabolic complications. | uk_UA |
| dc.language.iso | en | uk_UA |
| dc.publisher | AccScience Publishing | en |
| dc.subject | Gut microbiota | uk_UA |
| dc.subject | Obesity | uk_UA |
| dc.subject | Gut dysbiosis | uk_UA |
| dc.subject | Intestinal barrier | uk_UA |
| dc.subject | Metabolic dysfunction | uk_UA |
| dc.subject | Metabolic dysfunction-associated steatotic liver disease | uk_UA |
| dc.title | Obesity-associated gut dysbiosis: Metabolic dysfunction-associated steatotic liver disease as a clinical model of host–microbiome interactions | uk_UA |
| dc.type | Article | uk_UA |